<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id>
      <journal-title-group>
        <journal-title>The Journal of Headache and Pain</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1129-2369</issn>
      <issn pub-type="epub">1129-2377</issn>
      <publisher>
        <publisher-name>Springer Milan</publisher-name>
        <publisher-loc>Milan</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">20517705</article-id>
      <article-id pub-id-type="pmc">3452276</article-id>
      <article-id pub-id-type="publisher-id">225</article-id>
      <article-id pub-id-type="doi">10.1007/s10194-010-0225-0</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Are Cox-2 drugs the second line option in indomethacin responsive headaches?</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Porta-Etessam</surname>
            <given-names>Jes&#xFA;s</given-names>
          </name>
          <address>
            <phone>+91-34-667062490</phone>
            <email>jporta@yahoo.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cuadrado</surname>
            <given-names>Marialuz</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rodr&#xED;guez-G&#xF3;mez</surname>
            <given-names>Octavio</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Garc&#xED;a-Ptacek</surname>
            <given-names>Sara</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Valencia</surname>
            <given-names>Cristina</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Headache Unit, Hospital Universitario Cl&#xED;nico San Carlos, C/ Andr&#xE9;s Torrej&#xF3;n, 15, 7&#xBA;, 28014 Madrid, Spain </aff>
        <aff id="Aff2"><label>2</label>Neurology Department, Hospital Universitario Cl&#xED;nico San Carlos, Madrid, Spain </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>2</day>
        <month>6</month>
        <year>2010</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>10</month>
        <year>2010</year>
      </pub-date>
      <volume>11</volume>
      <issue>5</issue>
      <fpage>405</fpage>
      <lpage>407</lpage>
      <history>
        <date date-type="received">
          <day>21</day>
          <month>2</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>5</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Springer-Verlag 2010</copyright-statement>
      </permissions>
      <abstract id="Abs1">
        <p>Paroxysmal hemicrania and hemicrania continua are both indomethacin-responsive headaches. Although indomethacin use to be well tolerated, some patients developed gastrointestinal side effects. We report four cases of hemicrania continua and a patient suffering chronic paroxysmal hemicrania completely responsive to celecoxib. In our experience celecoxib is a good option treatment for patients suffering from hemicrania continua or chronic paroxysmal hemicranea that presents indomethacin adverse effects.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Hemicrania continua</kwd>
        <kwd>Chronic paroxysmal hemicrania</kwd>
        <kwd>COX-2</kwd>
        <kwd>Celecoxib</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag 2010</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Paroxysmal hemicrania and hemicrania continua are both indomethacin-responsive headaches. Although indomethacin is usually well tolerated, some patients developed gastrointestinal side effects, specially those patients who require long term therapy [<xref ref-type="bibr" rid="CR1">1</xref>]. Therefore, the use of cyclo-oxygenase-2 specific inhibitors could reduce secondary effects and they are essentially equipotent to indomethacin in vitro and in vivo [<xref ref-type="bibr" rid="CR2">2</xref>]. Indeed, some reports in the literature indicate the usefulness of the COX-2 inhibitors in the treatment of indomethacin-responsive headaches [<xref ref-type="bibr" rid="CR3">3</xref>&#x2013;<xref ref-type="bibr" rid="CR8">8</xref>]. We report four cases of hemicrania continua and a patient suffering chronic paroxysmal hemicrania completely responsive to COX-2 inhibitors.</p>
    </sec>
    <sec id="Sec2">
      <title>Case reports</title>
      <sec id="Sec3">
        <title>Case 1</title>
        <p>A 42&#xA0;years-old woman had sudden onset of short-lived pains on the left side of her head. She described the pain periorbital in localisation. She suffers for a month an intense headache with short attacks (about 5&#x2212;10&#xA0;min) but high frequency (10&#x2212;18 attacks per day). The pain associated with lacrimation and nasal congestion, but not pupil changes. Intensity was 8/10 in VAS. Her physical and neurological examinations and a head MRI were absolutely normal. We put her on indomethacin 25&#xA0;mg 3&#xA0;times a day, and in 24&#xA0;h her hemicranial pain completely disappears. Because of legs oedema we discontinued indomethacin and 1&#xA0;week later the pain returned. We introduced celecoxib 200&#xA0;mg per day with total recovery. After 12&#xA0;months of follow up she is still pain free.</p>
      </sec>
      <sec id="Sec4">
        <title>Case 2</title>
        <p>A 56&#xA0;years-old man present with an 8&#xA0;month history of a continuous left-sided headache strictly unilateral. The pain was moderate in intensity but fluctuating (between 2 and 7/10 VAS). The pain exacerbations were associated with lacrimation but not phono, photofobia, nausea or vomiting. An MRI was normal and indomethacin 25&#xA0;mg 3&#xA0;times a day was started with completely recovery. Two-month later he started to have gastric symptoms, indomethacin was discontinued and the hemicrania return. With celecoxib 200&#xA0;mg twice a day the hemicrania disappears. After 10&#xA0;month the patient is still asymptomatic.</p>
      </sec>
      <sec id="Sec5">
        <title>Case 3</title>
        <p>A 78&#xA0;years-old woman with 1&#xA0;year history of continuous and strictly left-sided headache, fluctuating in intensity (3&#x2212;9 in VAS) and accompanied by conjuntival injection and nasal congestion during exacerbation time. A cranial MRI was normal. With indomethacin 50&#xA0;mg 3&#xA0;times a day the hemicrania disappear, however, she developed disabling subjective tinnitus 1&#xA0;month later. We discontinued indomethacin and introduced celecoxib 200&#xA0;mg twice a day with completely recovery that persists 18&#xA0;month later.</p>
      </sec>
      <sec id="Sec6">
        <title>Case 4</title>
        <p>A 64&#xA0;years-old woman with 3&#xA0;years history of right-sided headache, fluctuating in intensity (2&#x2212;8 in VAS). She referred rhinorrhea and lacrimation only during headache exacerbation time. A cranial MRI was normal. With indomethacin 25&#xA0;mg 3&#xA0;times a day the hemicrania disappear, however, the patient suffer gastrointestinal disturbances. We discontinued indomethacin and introduced celecoxib 200&#xA0;mg twice a day with completely recovery that persists 10&#xA0;month later.</p>
      </sec>
      <sec id="Sec7">
        <title>Case 5</title>
        <p>A 76&#xA0;years-old man with 6&#xA0;month history of continuous left-sided headache and facial pain. He scored the pain between 4&#x2212;9 in VAS. The pain exacerbations were associated with lacrimation. A cranial MRI was normal. With indomethacin 25&#xA0;mg 3&#xA0;times a day the hemicrania disappear. After 2&#xA0;weeks on indometacina he complaint about pyrosis, that persists after omeprazol 40&#xA0;mg per day. We decided to discontinue indomethacin and introduced celecoxib 200&#xA0;mg twice a day with completely recovery that persists 6&#xA0;month later.</p>
      </sec>
    </sec>
    <sec id="Sec8" sec-type="discussion">
      <title>Discussion</title>
      <p>We present five patients suffering indomethacin-responsive headache case 1 suffering from paroxysmal hemicranias and cases from 2 to 5 from hemicranias continua (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). All of them have absolutely response to indomethacin, but the presence of adverse reactions or intolerability let us discontinued and introduce celecoxib with completely recovery of the symptoms.<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Clinical characteristics of the patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Case</th><th align="left">Age</th><th align="left">Gender</th><th align="left">Headache type</th><th align="left">Side</th><th align="left">Doses (mg)</th><th align="left">Time in month</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">42</td><td align="left">F</td><td align="left">HP</td><td align="left">Left</td><td align="left">200</td><td char="." align="char">12</td></tr><tr><td align="left">2</td><td align="left">56</td><td align="left">M</td><td align="left">HC</td><td align="left">Left</td><td align="left">400</td><td char="." align="char">10</td></tr><tr><td align="left">3</td><td align="left">78</td><td align="left">F</td><td align="left">HC</td><td align="left">Left</td><td align="left">400</td><td char="." align="char">18</td></tr><tr><td align="left">4</td><td align="left">64</td><td align="left">F</td><td align="left">HC</td><td align="left">Right</td><td align="left">400</td><td char="." align="char">10</td></tr><tr><td align="left">5</td><td align="left">76</td><td align="left">M</td><td align="left">HC</td><td align="left">Left</td><td align="left">400</td><td char="." align="char">6</td></tr></tbody></table><table-wrap-foot><p>All doses correspond to celecoxib</p><p><italic>F</italic> female, <italic>M</italic> male, <italic>HC</italic> hemicrania continua, <italic>HP</italic> hemicrania paroxistica</p></table-wrap-foot></table-wrap></p>
      <p>Indomethacin is consider the first-choice drug for the treatment of &#x201C;indomethacin-responsive headaches&#x201D;, and the headache resolution is consider as a diagnosis criteria in some of theses headaches. Sometimes patients develop side effects that require us to look for other therapeutic options. Although other drugs have been reported as useful treatment, most of them are anecdotic or single cases [<xref ref-type="bibr" rid="CR9">9</xref>&#x2013;<xref ref-type="bibr" rid="CR15">15</xref>]. Other anti-inflammatory drugs that have been demonstrated as alternative drugs, in particular piroxicam, however, their efficacy is lower when compared with indomethacin [<xref ref-type="bibr" rid="CR16">16</xref>]. The pathophysiology of theses &#x201C;indomethacin-response headache&#x201D; are still unknown, but the cyclo-oxygenase (COX)-2 should be implicated in the pathogenesis.</p>
      <p>Celecoxib have been previously reported to be effective in the treatment of other indomethacin-responsive headache [<xref ref-type="bibr" rid="CR3">3</xref>&#x2013;<xref ref-type="bibr" rid="CR11">11</xref>], however, there was no absolutely response in all patients [<xref ref-type="bibr" rid="CR4">4</xref>]. Anyhow, in our experience celecoxib is a good option treatment for patients suffering from hemicrania continua or chronic paroxysmal hemicranea that presents indomethacin adverse effects.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Conflict of interest</title>
      <p>None.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pareja</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Caminero</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Franco</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Casado</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Pascual</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>S&#xE0;nchez del R&#xEC;o</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Dose, efficacy and tolerability of longterm indomethacin treatment of chronic paroxysmal hemicrania and hemicrania continua</article-title>
          <source>Cephalalgia</source>
          <year>2001</year>
          <volume>21</volume>
          <fpage>906</fpage>
          <lpage>910</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1468-2982.2001.00287.x</pub-id>
          <pub-id pub-id-type="pmid">11903285</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Prasit</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Brideau</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The discovery of rofecoxib, [MK 966, Vioxx, 4-(4&#xA0;k-methylsulfonylphenyl)-3-phenyl-2 (5H)-furanone], an orally active cyclooxygenase-2-inhibitor</article-title>
          <source>Bioorg Med Chem Lett</source>
          <year>1999</year>
          <volume>5</volume>
          <issue>9</issue>
          <fpage>1773</fpage>
          <lpage>1778</lpage>
          <pub-id pub-id-type="doi">10.1016/S0960-894X(99)00288-7</pub-id>
          <pub-id pub-id-type="pmid">10406640</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wheeler</surname>
              <given-names>SD</given-names>
            </name>
          </person-group>
          <article-title>Rofecoxib-responsive hemicrania continua</article-title>
          <source>Headache</source>
          <year>2000</year>
          <volume>40</volume>
          <fpage>436</fpage>
          <lpage>437</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1526-4610.2000.00078.x</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peres</surname>
              <given-names>MFP</given-names>
            </name>
            <name>
              <surname>Zukerman</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Hemicrania continua responsive to rofecoxib</article-title>
          <source>Cephalalgia</source>
          <year>2000</year>
          <volume>20</volume>
          <fpage>130</fpage>
          <lpage>131</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1468-2982.2000.00029.x</pub-id>
          <pub-id pub-id-type="pmid">10961770</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Piovesan</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Zukerman</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kowacs</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Werneck</surname>
              <given-names>LC</given-names>
            </name>
          </person-group>
          <article-title>COX-2 inhibitor for the treatment of idiopathic stabbing headache secondary to cerebrovascular diseases</article-title>
          <source>Cephalagia</source>
          <year>2002</year>
          <volume>22</volume>
          <fpage>197</fpage>
          <lpage>200</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1468-2982.2002.00346.x</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lisotto</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Maggioni</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mainardi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Zanchin</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Rofecoxib for the treatment of chronic paroxysmal hemicrania</article-title>
          <source>Cephalalgia</source>
          <year>2003</year>
          <volume>23</volume>
          <fpage>318</fpage>
          <lpage>320</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1468-2982.2003.00500.x</pub-id>
          <pub-id pub-id-type="pmid">12716352</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Siow</surname>
              <given-names>HC</given-names>
            </name>
          </person-group>
          <article-title>Seasonal episodic paroxysmal hemicrania responding to cyclooxygenase-2 inhibitors</article-title>
          <source>Cephalalgia</source>
          <year>2004</year>
          <volume>24</volume>
          <fpage>414</fpage>
          <lpage>415</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1468-2982.2003.00695.x</pub-id>
          <pub-id pub-id-type="pmid">15096232</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peres</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Silberstein</surname>
              <given-names>SD</given-names>
            </name>
          </person-group>
          <article-title>Hemicrania continua responds to cyclo-oxygenase 2 inhibitors</article-title>
          <source>Headache</source>
          <year>2002</year>
          <volume>42</volume>
          <fpage>530</fpage>
          <lpage>531</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1526-4610.2002.02131.x</pub-id>
          <pub-id pub-id-type="pmid">12167145</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O&#x2019;Connor</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Phelan</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Regan</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Primary stabbing headache can be responsive to etoricoxib, a selective COX-2 inhibitor</article-title>
          <source>Eur J Neurol</source>
          <year>2008</year>
          <volume>15</volume>
          <fpage>e1</fpage>
          <pub-id pub-id-type="doi">10.1111/j.1468-1331.2007.01962.x</pub-id>
          <pub-id pub-id-type="pmid">18171381</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O&#x2019;Connor</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Phelan</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Regan</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>The use of etoricoxib to treat an idiopathic stabbing headache: a case report</article-title>
          <source>J Med Case Reports</source>
          <year>2007</year>
          <volume>1</volume>
          <fpage>100</fpage>
          <pub-id pub-id-type="doi">10.1186/1752-1947-1-100</pub-id>
          <pub-id pub-id-type="pmid">17883876</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferrante</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Tassorelli</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lisotto</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nappi</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Focus on therapy of primary stabbing headache</article-title>
          <source>J Headache Pain</source>
          <year>2010</year>
          <volume>11</volume>
          <fpage>157</fpage>
          <lpage>160</lpage>
          <pub-id pub-id-type="doi">10.1007/s10194-010-0189-0</pub-id>
          <pub-id pub-id-type="pmid">20119679</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hannerz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ericson</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bergstrand</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Chronic paroxysmal hemicrania: orbital phlebography and steroid treatment. A case report</article-title>
          <source>Cephalalgia</source>
          <year>1987</year>
          <volume>7</volume>
          <fpage>189</fpage>
          <lpage>192</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1468-2982.1987.0703189.x</pub-id>
          <pub-id pub-id-type="pmid">3652201</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wamer</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Wamil</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>McLean</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Acetazolamide for the treatment of chronic paroxysmal hemicrania</article-title>
          <source>Headache</source>
          <year>1994</year>
          <volume>34</volume>
          <fpage>597</fpage>
          <lpage>599</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1526-4610.1994.hed3410597.x</pub-id>
          <pub-id pub-id-type="pmid">7843957</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coria</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Claveria</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Jimenez-Jimenez</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Seijas</surname>
              <given-names>EV</given-names>
            </name>
          </person-group>
          <article-title>Episodic paroxysmal hemicrania responsive to calcium channel blockers</article-title>
          <source>J Neurol Neurosurg Psychiatry</source>
          <year>1992</year>
          <volume>55</volume>
          <fpage>166</fpage>
          <pub-id pub-id-type="doi">10.1136/jnnp.55.2.166</pub-id>
          <pub-id pub-id-type="pmid">1538227</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Evers</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Husstedt</surname>
              <given-names>IW</given-names>
            </name>
          </person-group>
          <article-title>Alternatives in drug treatment of chronic paroxysmal hemicrania</article-title>
          <source>Headache</source>
          <year>1996</year>
          <volume>36</volume>
          <fpage>429</fpage>
          <lpage>432</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1526-4610.1996.3607429.x</pub-id>
          <pub-id pub-id-type="pmid">8783475</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sjaastad</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Antonaci</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>A piroxicam derivative partly effective in chronic paroxysmal hemicrania and hemicrania continua</article-title>
          <source>Headache</source>
          <year>1995</year>
          <volume>35</volume>
          <fpage>549</fpage>
          <lpage>550</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1526-4610.1995.hed3509549.x</pub-id>
          <pub-id pub-id-type="pmid">8530280</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
